New Article: Advancing Antibody Research Against SARS-CoV-2 Variants

At TrimLAB, we are committed to pioneering computational biology research to develop innovative therapeutic solutions. Our latest publication, "Development of an Antibody Targeting Variants of the SARS-CoV-2 Spike Protein," addresses the challenges posed by evolving COVID-19 variants in the Journal of Health Science and Medical Research (JHSMR). (Our Work)

Congrats to our proud MS student, Puridech Bubphamanee, and our team for their valuable contributions!

Key Findings

We enhanced the binding efficacy of a SARS-CoV-2 antibody fragment by designing single-chain variable fragments (scFv) to block ACE2 from binding receptor binding domain (RBD) variants. Using molecular docking and dynamic simulations, we found that the R105W mutation significantly improved binding affinity and stability, especially against the Delta and Omicron variants. This mutation effectively interacted with conserved residues (Y452, F486, and Y489), making it a strong therapeutic candidate.

Impact and Future Directions

Our findings highlight the importance of adaptive antibody design in combating SARS-CoV-2 and future pandemics. TrimLAB remains dedicated to advancing computational and experimental methodologies for global health challenges.

Explore our latest publication and stay connected with TrimLAB for future breakthroughs.